Oswald Bentinck
Company: Rocket Pharmaceuticals
Job title: Vice President, Head of Global Value & Access
Bio:
Oswald currently serves as Global Head of Value and Access at Rocket Pharmaceuticals, a clinical-stage biotech, advancing an integrated pipeline of LVV & AAV genetic therapies that correct the root cause of complex and rare life-threatening childhood hematological disorders and cardiomyopathies. He joined Rocket in August 2022.
Before Rocket, Oswald was Head of Value and Access EMEA at AveXis/Novartis Gene Therapies that successfully launched Zolgensma, a gene therapy for spinal muscular atrophy (SMA). Earlier Oswald worked in various regional and global marketing and market access roles at Pfizer, Shire, and Alexion. He has over 20 years’ commercial experience in the pharmaceutical industry with 14 of those focusing on rare diseases.
Seminars:
Talk Details to be Announced Shortly 2:30 pm
day: Conference Day One
Panel Discussion: Designing a Clinical Development Program to Support Future Market Access 4:55 pm
What are the critical market access steps when entering the clinic? Bridging the gap between early-phase development and commercial: how can market access push for payer- and patientrelevant endpoints to be included in phase 1 study designs? Practical advice when designing a clinical program for an intended first-in-class therapy Does engagement with Medicare look the…Read more
day: Conference Day One